| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Previous Article | Next Article ![]()
Antimicrobial Agents and Chemotherapy, June 2008, p. 2175-2182, Vol. 52, No. 6
0066-4804/08/$08.00+0 doi:10.1128/AAC.01420-07
Copyright © 2008, American Society for Microbiology. All Rights Reserved.

Research Institute of Physico-Chemical Medicine, Moscow, Russian Federation,1 Central Research Institute of Dermatology and Venerology, Moscow, Russian Federation,2 National Research Centre for Antibiotics, Moscow, Russian Federation3
Received 2 November 2007/ Returned for modification 15 January 2008/ Accepted 20 March 2008
| ABSTRACT |
|---|
|
|
|---|
4 µg/ml, the blaTEM-1 gene was detected in 12. The Tet(M) determinant was found in 4 of 12 N. gonorrhoeae isolates with tetracycline MICs of
16 µg/ml. The chromosomal genetic markers of penicillin and tetracycline resistance were detected especially in isolates with penicillin MICs of 0.25 to 2.0 µg/ml and tetracycline MICs of 0.5 to 4 µg/ml. Mutations in GyrA and ParC were found in 208 of 211 quinolone-resistant N. gonorrhoeae isolates. This work is the first representative molecular research of the N. gonorrhoeae population in Russia. Information about the prevalence of antibiotic resistance mechanisms and the positive predictive value of certain genetic determinants is given. The positive predictive values of the analyzed genetic markers were found to be different for fluoroquinolones (90.3%), penicillin (91.1%), and tetracycline (81.9%). | INTRODUCTION |
|---|
|
|
|---|
Beta-lactams, fluoroquinolones, and spectinomycin are recommended for the treatment of gonorrhea by national and international guidelines (17), and tetracyclines are also used in countries with limited resources. The genetic mechanisms of N. gonorrhoeae resistance to antibacterials are complicated and not definitely elucidated. However, acquisition of some genes and a number of mutations in structural genes and regulatory regions are considered to be involved unambiguously in resistance development.
Resistance to penicillin can be mediated by the production of TEM-1 beta-lactamase, encoded by the plasmid-borne blaTEM-1 gene, or by mutations in a number of chromosomal genes (2, 21, 22, 25). It has been proposed that resistance due to chromosomal mutations is a result of a complicated interplay between reduced affinities of modified penicillin-binding proteins (encoded by the penA and ponA genes) to penicillin, activation of the MtrC-MtrD-MtrE efflux pump (by mutation in the promoter region of the mtrR gene), and reduction in the permeation of the outer membrane porin PorB1b (encoded by porB1b) (i.e., by penB mutations) (4, 9, 10, 19, 23). It is likely that mutations in the pilQ gene, encoding a protein of the secretin family, are also involved in the development of resistance to penicillin (32).
Resistance to tetracycline is also mediated by different mechanisms, including high-level resistance due to acquisition of the tet(M) gene, encoding a ribosome-protecting protein (18), and low-level resistance due to a combination of target modification (mutation in the rpsJ gene, encoding ribosomal protein S10), derepressed efflux (mtrR gene), and reduced permeation (porB1b gene) (9, 10, 11, 19). Involvement of the last two mechanisms in the development of resistance to both penicillin and tetracyclines can explain the high frequency of associated resistance to these antibacterials in clinical isolates of chromosomally resistant N. gonorrhoeae.
Mechanisms of fluoroquinolone resistance in N. gonorrhoeae are not as complicated as those of resistance to beta-lactams and involve mutations in gyrA and parC genes (5, 28). Reduction of cell permeation and efflux activation can participate in the increase of fluoroquinolone MICs for N. gonorrhoeae, but the significance of these mechanisms is not obvious (6, 15).
The aims of this study were to reveal the correlation between the presence of known resistance determinants and the levels of susceptibility of clinical N. gonorrhoeae isolates to penicillin, tetracycline, and fluoroquinolones and to evaluate the usefulness of detection of these determinants for clinical resistance prediction.
Standard PCR combined with matrix-assisted laser desorption ionization-time-of-flight (MALDI-TOF) mass spectrometry-based minisequencing or a sequencing procedure was used for the detection of single-nucleotide polymorphisms (SNPs) associated with antimicrobial resistance. This method is based on enzymatic extension of an oligonucleotide primer annealing close to a polymorphic site, using a deoxynucleoside triphosphate-dideoxynucleoside triphosphate (dNTP-ddNTP) mixture. The SNPs in the analyzed genes were detected by measurement of the molecular weights of reaction products. This technique is as accurate as direct sequencing for SNP identification but is far simpler and less expensive. Previously, this method was applied successfully for hepatitis C virus genotyping (13).
(Parts of this work were presented at the 46th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, CA, 14 to 17 September 2006.)
| MATERIALS AND METHODS |
|---|
|
|
|---|
Genotypic characterization. Total genomic DNAs from N. gonorrhoeae isolates were obtained according to the method of Boom et al. (1). If necessary, the prepared DNA samples were stored at a temperature of –20°C.
(i) Conventional PCR for detection of blaTEM-1 and tet(M) genes. Genomic DNA was used as a template, and the oligonucleotide primers are described in Table 1. Amplification was carried out in a 10-µl reaction mixture containing 66 mM Tris-HCl, pH 9.0, 16.6 mM (NH4)2SO4, 2.5 mM MgCl2, a 0.2 mM concentration of each dNTP, 5 pmol of each primer, and 1 unit of Taq polymerase (Fermentas, Lithuania) under the following conditions: 94°C for 20 s, 60°C for 20 s, and 72°C for 15 s for 35 cycles. A programmed Tetrad DNA Engine thermocycler (MJ Research, Inc.) was used. The amplification products were analyzed by means of electrophoresis on a 2% agarose gel.
|
Dephosphorylation of the 5'-end phosphate groups of dNTPs in the postamplification reaction mixture was done by incubation with 0.5 U of shrimp alkaline phosphatase (Fermentas, Lithuania) for 20 min at 37°C, followed by inactivation of the enzyme by heating for 10 min at 85°C.
Minisequencing reactions were carried out with the amplicons of all genes of interest, obtained by conventional PCR with original internal primers designed for each particular SNP (Table 2) in such a way that, after annealing, their 3' ends were close to polymorphic sites. In the presence of certain dNTPs and ddNTPs in the reaction mixture, these primers were extended in accordance with the nucleotide sequence of the complementary chain. Hence, the reaction products were different for wild (native) and mutant types. The SNPs were detected by measurement of the molecular masses of the reaction products by means of MALDI-TOF mass spectrometry and comparison to the theoretical molecular masses.
|
|
The minisequencing reaction products were purified using a SpectroCLEAN kit (Sequenom USA) according to the manufacturer's instructions.
A sample aliquot (0.2 to 1 µl) was spotted onto the matrix, which was preliminarily dried on AnchorChip (Bruker Daltonics, Germany) 400-µm targets. The matrix employed was a saturated solution of 3-hydroxypicolinic acid (Fluka, Germany) in a 1:1 acetonitrile-water mixture (Merck, Germany) mixed with 0.4 M dibasic ammonium citrate (Fluka, Germany) at 9:1 (vol/vol) ratio. All solvents were of a quality suitable for mass spectrometry. Mass spectra were collected on a Reflex IV MALDI-TOF mass spectrometer (Bruker Daltonics, Germany) that was operated in the positive linear mode. A 337-nm nitrogen laser with a 9-Hz pulse frequency was used. Mass spectrometer parameters were optimized for the range of m/z values from 1,000 to 10,000, using a peptide standard set for calibration. Each mass spectrum was collected with 30 laser pulses at constant laser power and a constant threshold value in order to enhance the resolution.
(iii) Sequencing procedure for analysis of porB1 and parC gene changes. PCRs were performed with the corresponding primer sets (Table 1) under the same conditions as those described above. DNA sequence analysis was performed by the modified Sanger method, using an ABI Prism BigDye Terminator cycle sequencing ready reaction kit and an ABI Prism 3100 genetic analyzer (Applied Biosystems; Hitachi, Japan) according to the manufacturer's instructions.
Analysis of the nucleotide sequence as well as of deduced amino acid sequences was performed using Vector NTI Advance v. 9.0 software (Infomarks Inc.).
Por typing of N. gonorrhoeae isolates. N. gonorrhoeae typing based on analysis of por gene variability was done as described previously (8, 14, 24, 30). The por type of a particular isolate was determined by identification of the obtained nucleotide sequences of the porB1 genes in the EMBL (European Molecular Biology Laboratory) and NCBI (National Center for Biotechnology Information) databases.
Statistical analysis.
Associations between genetic factors and susceptibility categories were examined by using chi-square (
2) and Cramer (V) tests. All statistical calculations were two-tailed and were conducted with the significance set at P values of <0.05. Statistical analyses were performed with STATISTICA 6.0 software.
| RESULTS |
|---|
|
|
|---|
Genotypes and penicillin susceptibility.
Among isolates included in the study, 120 (25.9%) were susceptible to penicillin, 289 (62.2%) had intermediate susceptibility, and 55 (11.9%) were resistant. The penicillin MIC distribution for isolates with different genotypes is shown in Table 3. The wild type (no mutations in target genes and no blaTEM-1 gene) was detected in 54 (11.6%) isolates and was significantly associated with clinical susceptibility (
2 = 134.3; P < 0.001).
|
Analysis of the PorB1b protein (PenB locus) revealed that 225 (48.5%) isolates possessed two different combinations of amino acid substitutions at positions 120 and 121, which have been regarded as critical in mediating resistance to penicillin and tetracycline (9, 19). The combination of a Gly120
Lis mutation with an Ala121
Asp mutation was found in 115 isolates, and a Gly120
Asp mutation with an Ala121
Asn mutation was found in 74 isolates. Because all of these mutations led to the same effect in the following analysis, we did not discriminate them in individual isolates and considered them together as penB mutants (penBmut).
Within the mtrR region, the following changes were detected: amino acid substitution Gly45
Asp in the MtrR protein (72 isolates) and nucleotide mutation –35delA in the gene's promoter (170 isolates). It should be noticed that among the isolates, 19 carried both mutations simultaneously. Taking into account that both mutations led to overexpression of the MtrC-MtrD-MtrE efflux pump (23, 29) and that a cumulative effect had not been shown, we considered them together to be mtrR mutants (mtrRmut).
Three genotypes (penAmut penBmut, penAmut mtrRmut, and penAmut penBmut mtrRmut) were detected in 7, 15, and 6 isolates, respectively. An obvious trend toward higher MICs for isolates with these genotypes than those for wild-type isolates was observed, but the correlation with clinical nonsusceptibility was not significant (P > 0.05). The genotypes with isolated mutations in mtrR and penB were observed in one and two isolates, respectively, with a penicillin MIC of 0.015 µg/ml.
Four genotypes (ponAmut penAmut, ponAmut penAmut mtrRmut, ponAmut penAmut penBmut, and ponAmut penAmut penBmut mtrRmut) were more prevalent and were detected in 39 (8.4%), 62 (13.4%), 76 (16.4%), and 133 (28.7%) isolates, respectively. All of these genotypes were significantly associated with clinical nonsusceptibility (
2 = 281.7; P < 0.001). The highest penicillin MICs were observed for 18 (3.9%) beta-lactamase-positive isolates, but in 8 of them the MICs varied from 1.0 to 4.0 µg/ml, while usually the production of beta-lactamases is associated with values of
8.0 µg/ml. The relationship between the analyzed groups (genotype, as a complex of known genetic markers, and phenotype) was confirmed by the Cramer factor, which was found to be 0.64 for penicillin resistance.
Genotypes and tetracycline susceptibility.
One hundred sixty-seven (35.9%) isolates were susceptible to tetracycline, 121 (26.0%) had intermediate susceptibility, and 176 (38.1%) were resistant. The tetracycline MIC distribution for isolates with different genotypes is shown in Table 4. The wild type [no mutations in genes involved in development of resistance and no tet(M) gene] was detected in 91 (19.6%) isolates and was significantly associated with clinical susceptibility (
2 = 116.7; P < 0.001).
|
Met in the rpsJ gene (rpsJmut) was found in 59 (12.7%) isolates. In comparison to wild-type isolates, an obvious shift toward higher MIC values was observed for isolates harboring mutations in the rpsJ gene, but the association was not statistically significant.
Three genotypes (rpsJmut mtrRmut, rpsJmutpenBmut, and rpsJmut penBmut mtrRmut) were more prevalent and were detected in 78 (16.8%), 87 (18.8%), and 139 (30%) isolates, respectively. All of these genotypes were significantly associated with clinical nonsusceptibility (
2 = 163.1; P < 0.001). The association between the analyzed groups (genotype, as a complex of known genetic markers, and phenotype) was confirmed by the Cramer factor, which was found to be 0.53 for tetracycline resistance.
Genotypes and ciprofloxacin susceptibility. Among the studied isolates, 251 (54.1%) were susceptible to ciprofloxacin, 2 (0.4%) had intermediate susceptibility, and 211 (45.5%) were resistant (Table 5).
|
Phe). The ParC alterations occurred in the QRNG region in 194 isolates, at residue Asp86, Ser87, or Glu91. Commonly, mutations in the parC gene were represented with the same frequencies as those in gyrA. Alterations in both gyrA and parC genes were found for 176 resistant strains with fluoroquinolone MICs of
4 µg/ml.
The wild type (no mutations in genes involved in resistance development) was detected in 148 (31.9%) isolates. In 85 (18.3%) isolates, mtrRmut was detected as a single resistance determinant; the ciprofloxacin MIC distribution for these isolates did not differ significantly from that for wild-type isolates. Both genotypes were significantly associated with clinical susceptibility (
2 = 180.8; P < 0.001).
Isolated mutations in ParC and a combination of a mutation in GyrA with mtrRmut were rare, and we were unable to find any significant association with a particular phenotype.
Four genotypes (gyrAmut, parCmut mtrRmut, gyrAmut parCmut, and gyrAmut parCmut mtrRmut) were detected in 17 (3.7%), 13 (2.8%), 70 (15.1%), and 119 (25.6%) isolates, respectively. All of these genotypes were significantly associated with clinical nonsusceptibility (
2 = 404.1; P < 0.001), and the Cramer factor was found to be 0.89 for fluoroquinolone resistance.
| DISCUSSION |
|---|
|
|
|---|
The nonclonal character of the analyzed strains was confirmed by por typing. Different genotypes were found for the whole group as well as for samples from a particular region of Russia.
Analysis of the prevalence of known resistance determinants in a large set of clinical isolates of N. gonorrhoeae indicates that their absence is associated with clinical susceptibility to penicillin, tetracyclines, and fluoroquinolones. The majority of isolates carrying penBmut, mtrRmut, penAmut, or rpsJmut as a single genetic marker demonstrated some antibiotic MIC shift toward higher values than those for wild-type isolates, but nevertheless, they remained in the susceptible category. As far as penB and mtrR mutations are concerned, this statement is in agreement with the observations that mutations in PorB1b have no effect alone and that both mtrR and penB mutations are required to decrease permeability of the cell membrane and to develop antimicrobial resistance in gonococci (20, 27).
Most of the penicillin-resistant N. gonorrhoeae strains either carried the blaTEM-1 gene or had different combinations of nucleotide substitutions in the penA, mtrR, penB, or ponA gene. The presence of the blaTEM-1 gene was observed in 12 strains with high-level resistance to penicillin (MICs = 4.0 to 16.0 µg/ml), but for six blaTEM-1-positive isolates the MICs of penicillin varied from 1.0 µg/ml to 2.0 µg/ml. This may be explained by a decreased β-lactamase activity due to amino acid substitutions. However, whole blaTEM-1 gene sequencing did not reveal any alterations (data not shown). This phenomenon requires further investigation. Nevertheless, the difference between susceptible and resistant groups for that genotype (blaTEM-1) was found to be reliable (P < 0.001).
An isolated alteration in the penA gene was found only for 51 isolates. Insertion of an aspartic acid (Asp345a) in PBP2 was linked to the decreased rate of acylation by penicillin (7) and to an increase of the antibiotic MIC to 0.12 to 0.25 µg/ml and is considered to be the first step in the acquisition of high-level resistance to penicillin (2). However, the distribution of penicillin MICs for isolates possessing this mutation as a single possible mechanism of resistance to penicillin was bimodal, with peaks at 0.015 µg/ml and 0.12 µg/ml. Probably, additional mutations in penA or other genes are necessary for the expression of resistance, and the development of compensatory mutations is less likely. The absence of a statistically significant correlation between susceptible and nonsusceptible strains (P > 0.05) confirmed the ambiguous impact of penA mutation on penicillin resistance phenotype formation. Similar data were obtained for 28 strains which had penA alteration with additional mutations in penB or mtrR loci.
The combination of mutations in both the penA and ponA genes with any nucleotide sequence in penB or mtrR loci was shown for 310 strains, especially those with penicillin MICs of 0.5 to 1.0 µg/ml. Previously, it was shown that a Leu421
Pro substitution in PBP1 (ponA gene) was involved in high-level penicillin resistance of gonorrhea, but only as an additional locus (25). Our data are not in complete agreement with this finding. Among the strains examined, only those with mutations in both the ponA and penA loci were found, especially for N. gonorrhoeae strains with MICs of 0.12 to 1.0 µg/ml. The high-level penicillin-resistant strains had alterations in almost all loci studied, i.e., penA, ponA, penB, and mtrR. Nevertheless, significant differences between strains that were susceptible and nonsusceptible to penicillin were found for all of these genotypes (P < 0.001). This was the reason that genotypes ponAmut penAmut, ponAmut penAmut mtrRmut, ponAmut penAmut penBmut, and ponAmut penAmut penBmut mtrRmut were selected as predictive of antimicrobial resistance of N. gonorrhoeae to penicillin.
Although 12 N. gonorrhoeae strains were identified as having high-level resistance to tetracycline (MICs of
16 µg/ml), only 4 of them carried the plasmid-encoded Tet(M) determinant. For the remaining eight strains, it might be the contributions of other, unstudied chromosomally mediated mechanisms that result in high-level tetracycline resistance. Ninety-one isolates that had neither tet(M) nor alterations in rspJ, mtrR, and penB loci were susceptible or intermediately resistant to tetracycline (MICs of <1.0 µg/ml). A similar trend was observed for six strains with mutations only in either mtrR or penB loci.
The amino acid substitution Val45
Met in ribosomal protein S10 (encoded by the rpsJ gene) was found for 363 N. gonorrhoeae strains. Fifty-nine samples revealed only an rpsJ nucleotide alteration. Among them, 18 were susceptible to tetracycline, with MICs of <0.25 µg/ml, and the others were nonsusceptible (30 were intermediately resistant strains with MICs of 0.5 to 1.0 µg/ml, and 11 had MICs of 2.0 to 4.0 µg/ml). As expected, we did not find significant differences in this marker between strains that were susceptible and resistant to tetracycline (P > 0.05). The point mutation in the rpsJ gene was initially described as an additional mechanism for chromosomally mediated tetracycline resistance in N. gonorrhoeae (11).
In most cases (n = 304), rpsJ alteration was combined with the mtrR and penB resistance determinants. A significant difference (P < 0.01) was found between strains that were susceptible and resistant to tetracycline for genotypes rpsJmut mtrRmut, rpsJmut penBmut, and rpsJmut penBmut mtrRmut. All of them were selected as considerable for the prediction of tetracycline resistance in N. gonorrhoeae, but it should be mentioned that the predictive markers of tetracycline resistance were selected with less significance than those for penicillin or fluoroquinolone resistance. This clearly shows that known genetic markers are not yet completely sufficient to explain the phenomenon of N. gonorrhoeae tetracycline resistance.
For most isolates, the association between the presence of particular mutations in the QRDR region and the fluoroquinolone resistance phenotype has been shown. In cases of fluoroquinolone resistance with substitutions analyzed in neither the GyrA nor ParC protein (six strains), one can suppose the existence of unknown alterations in the genes for gyrase and topoisomerase or the involvement of specific efflux mechanisms (26). As mentioned above, most QRNG regions exhibited double mutations at both positions in GyrA. Among the strains examined, we revealed one with a single mutation in GyrA that agrees with a low level of fluoroquinolone resistance (MIC = 0.25 µg/ml). The other, with a MIC of 0.12 µg/ml for ciprofloxacin, had no alterations in the analyzed loci.
A significant difference (P < 0.001) was found between strains that were susceptible and resistant to fluoroquinolones for genotypes gyrAmut, parCmut mtrRmut, gyrAmut parCmut, and gyrAmut parCmut mtrRmut. Thus, these genotypes were selected as considerable for prediction of fluoroquinolone resistance. Two other genotypes, gyrAmut mtrRmut and parCmut, were too rare, and it was impossible to evaluate their statistical significance. It looks like efflux derepression due to substitutions in the mtrR locus might play a role in fluoroquinolone resistance revealed by strains with altered ParC proteins.
Thus, based on the explanations described above, the analysis of the distributions of individual genetic markers and their combinations among susceptible and resistant N. gonorrhoeae strains allowed us to select particular genotypes for prediction of antimicrobial resistance to penicillin, tetracycline, and fluoroquinolones (set off with spaces in Tables 3, 4, and 5), with significance at P levels of <0.01. The average positive predictive values of these genetic determinants were found to be different for fluoroquinolones (90.3%), penicillin (91.1%), and tetracycline (81.9%).
The first representative molecular study of the prevalence of resistance mechanisms in a large set of N. gonorrhoeae clinical isolates allowed us to conclude that the surveillance of genetic changes may be useful for the prediction of clinical resistance, improvement of gonorrhea treatment, and prevention of disease spread.
| ACKNOWLEDGMENTS |
|---|
This work was supported by development contract BDALIPCM 270505 from Bruker Daltonik, Germany, and by development contract 24-05 from the Russian Agency of Health.
| FOOTNOTES |
|---|
Published ahead of print on 31 March 2008. ![]()
| REFERENCES |
|---|
|
|
|---|
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Clin. Vaccine Immunol. | Clin. Microbiol. Rev. |
|---|---|
| J. Clin. Microbiol. | ALL ASM JOURNALS |